A significantly higher reduction was found in high total AChE SMDCs receiving responder patients compared to low (p = 0.028) and medium (p = 0.035) total AChE SMDCs receiving responder patients, suggesting that injection of SMDCs with high total AChE activity results in better fecal incontinence treatment outcome in responders (Fig 5A). The gene discussed is ACHE; the disease is fecal incontinence.